A population-based lung cancer screening study in China reported results suggesting mortality benefit for never-smokers, according to the limited excerpt provided. The work covers a 2017 to 2021 enrollment period with seven years of follow-up, using a real-world screening framework in Guangzhou. If confirmed in the full dataset and methodology disclosure, the findings would be important because never-smokers are frequently underrepresented in screening evidence compared with current and former smokers. It would also support broader discussion about which risk groups should be targeted with repeated screening intervals. Stakeholders will be watching for effect size by stage at diagnosis, adherence and false-positive rates, and whether improvements stem from overdiagnosis tradeoffs or genuine mortality reduction.